Rubicon Research Limited IPO
Rubicon Research Limited IPO
Rubicon Research Limited IPO
₹ 461 / 30 Shares Shares
Minimum Investment
Rubicon Research Limited IPO
Listed on
16 Oct, 2025
Issues Price
₹461-485 per equity share
Rubicon Research Limited IPO
Open Date
09 Oct 2025
Close Date
13 Oct 2025
Lot Size
30.00
Min. Investment
₹ 461
Issue Price
₹ 461-485
Listing on
16 Oct, 2025
Issues Size
2,84,02,040 shares(aggregating up to ₹1377.5 crore)
Face Value
₹1 Per Equity Share
Total Shares Offered
30 Shares
Offered To Public
30 Shares
Rubicon Research Limited IPO
Rubicon Research IPO is a book-built issue of ₹1377.5 crores, The total issue size is ₹1377.5 crores. The IPO of Rubicon Research is priced at ₹461-485 per equity share, which has a face value of ₹1 Per Equity Share each, IPO bidding starts from Oct 9, 2025 and ends on Oct 13, 2025. The allotment for Rubicon Research IPO will be finalized on Oct 14, 2025. Rubicon Research IPO will be listed on BSE, NSE, with a tentative listing date fixed as Oct 16, 2025. The company shall list its equity shares on the BSE, NSE. Axis Capital Ltd IIFL Capital Services Ltd JM Financial Ltd SBI Capital Markets Ltd is the registrar of the issue. Retail investors can bid for a minimum of 30 shares, extendable to 14,550. S-HNIs will be able to bid for 420 shares at ₹2,03,700, while B-HNIs can also apply for a bid of 2,070 shares at ₹10,03,950. The book-running lead manager for the IPO is/are MUFG Intime India Pvt.Ltd.. The total issue ₹1377.5 crore, comprising a fresh issue of 1,03,09,278 shares ₹500 crore and having Offer for Sale (OFS) of 1,80,92,762 shares to mop up ₹877.5 crore. The Rubicon Research IPO sets its price band at 461-485 for each share. A single application for Rubicon Research Limited IPO must contain at least 30 shares. Sentiment investors need to invest a minimum of 30 through their retail account. For investors to prevent oversubscription issues, they should submit bids at the cutoff price, which estimates about ₹14,550 In order to participate in the sNII, investors must purchase at least 14 lots of 420 shares for ₹2,03,700, while the bNII requires 69 lots of 2,070 shares for an investment of ₹10,03,950.
Founded In
1999
Managing Director
Pratibha Pilgaonkar
Parent Organization
Rubicon Research Limited IPO
Application Details of Rubicon Research Limited IPO
| Apply as | Price Range | Apply Upto |
|---|---|---|
| Retail (min) | ₹ 461-485 | ₹14,550 |
| Retail(max) | ₹ 461-485 | ₹1,89,150 |
| SHNI(min) | ₹ 461-485 | ₹2,03,700 |
| SHNI(max) | ₹ 461-485 | ₹9,89,400 |
| BHNI(min) | ₹ 461-485 | ₹10,03,950 |
For Rubicon Research Limited IPO, eligible investors can apply as Regular.
Open On12 Dec 2025
Close On16 Dec 2025
Price Range₹2061-2165
Testimonial
Genuine Review Form Statisifed Customers
I’ve used a few platforms before, but KSquare is easily the most user-centric. Their mutual fund tools make planning easy and returns trackable.
I was impressed by how seamless KSquare’s NRI services are. They handled my documentation with care and helped me invest without unnecessary hassle.
KSquare provided a practical solution without liquidating my investments. I’m grateful for their clarity and quick process.
Starting SIPs with KSquare has brought so much clarity to my finances. Their platform is smooth, and the investment returns speak for themselves.
KSquare’s New Fund Offering updates are timely and insightful. I’ve participated in two NFOs already, and the results have been quite impressive and transparent.
Owning a home seemed difficult, but KSquare’s SIP planning made it achievable. Their regular guidance, timely suggestions, and disciplined investment approach gave me complete financial confidence throughout the journey.
KSquare’s mutual fund platform is exactly what I needed. It’s intuitive, offers diverse funds, and gives great insights. I’ve seen real growth since I started.
I use KSquare to manage my NRI investments. They provide clarity, legal compliance, and reliable support every step of the way. Excellent platform!
I started SIPs with KSquare six months ago and already see consistent growth. Their timely updates and reports make tracking easy. Definitely a smart decision for financial planning.
KSquare delivers excellent service and fund recommendations. The platform makes investing feel less like a chore and more like a plan I’m excited to follow.
FAQ's
Frequenlty Asked Question
Can US or Canadian NRIs invest through KSquare?
Currently, due to compliance issues, many mutual funds restrict US/Canada NRIs. KSquare can guide you on eligible options.
Does KSquare provide regular portfolio updates?
Yes, clients receive consistent performance updates and guidance, ensuring investments remain aligned with goals at every stage.
How does KSquare ensure compliance with FEMA rules?
KSquare’s advisory follows all FEMA guidelines, helping NRIs invest safely while staying compliant with Indian regulations.
Can I plan for a home or car purchase through SIP?
Absolutely, SIPs help accumulate funds steadily over time so major purchases like home or car become financially stress-free.
Are NFOs better suited for long-term investors?
NFOs are ideal for long-term investors who can wait for the fund to build performance and portfolio over time.
Which types of mutual funds are eligible for loans?
Typically, equity and debt mutual fund units held in demat form are eligible. KSquare helps confirm your fund’s eligibility instantly.
How does KSquare help in retirement planning?
KSquare builds long-term SIP strategies to create a secure retirement corpus based on future lifestyle, needs, and inflation.
Is it safe to invest in NPS?
NPS is regulated by PFRDA and offers transparency, safety, and steady growth through professional fund managers.
Ksquare Timeline Pvt. Ltd. is an AMFI Registered Mutual Fund Distributor having ARN No. 146262. Mutual Fund investments are subject to market risks. Please read all scheme related documents carefully before investing. This website is intended only for informational and self-help purposes and should not be considered as investment advice or return guarantee. Past performance is not indicative of future results. Terms & Conditions apply.